Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Neoadjuvant Recombinant Vaccinia Virus for Metastatic Colorectal Cancer With Liver Resection

9 settembre 2026 aggiornato da: Jennerex Biotherapeutics

A Phase IIa Study of Neoadjuvant JX-594 Administered by Intravenous Infusion or Intratumoral Injection Followed by Surgical Resection in Patients With Metastatic Colorectal Tumors Within the Liver

This is a neoadjuvant Phase 2a, open-label trial in patients with metastatic colorectal carcinoma who are undergoing a complete resection of the metastatic colorectal tumors in their liver.

Panoramica dello studio

Descrizione dettagliata

Patients will receive either an intravenous infusion or an intratumoral injection of JX-594 (Pexa-Vec) directly into one liver lesions at Day 1. Patients will undergo a complete resection of all liver tumors at Day 15. Patients will then be monitored throughout their life for disease recurrence and/or general overall survival.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

2

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Ontario
      • Ottawa, Ontario, Canada, K1H 8L6
        • Ottawa Hospital and Research Institute (OHRI)

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • The planned surgical resection must be margin negative with complete resection or resection plus radiofrequency ablation (RFA) of metastatic CRC as determined by principal investigator or surgeon
  • Diagnosis of histologically-confirmed metastatic colorectal tumor(s) within the liver eligible for surgical resection. Eligible patients must have: preoperative work-up that reveals potential resectability (CT scan or MRI of the abdomen and pelvis and CT scan of the chest within 6 weeks of enrollment) preoperative work-up to ensure operability with general medical clearance as indicated
  • At least one measurable tumor mass by MRI (i.e. lesion that can accurately be measured in at least one dimension with longest diameter ≥ 1 cm)
  • Plan for a maximum resection of six (6) liver segments
  • Child Pugh A (Refer to APPENDIX C: Child-Pugh Classification
  • Performance Score: KPS score of ≥ 70
  • Age ≥18 years
  • For patients treated with IT injection only: at least 1 intra-hepatic tumor with longest diameter (LD) ≥ 1.5 cm and ≤ 12 cm and which is technically amenable to injection under radiographic guidance targeted for surgical resection.
  • In patients treated with IT injection, the injected tumor must be included in the surgical resection specimen (a planned RFA of the injected tumor would not be eligible)
  • Total bilirubin ≤ 3 x ULN
  • AST, ALT < 5.0 x ULN
  • WBC ≥ 3.5x 109/L and ≤ 50 x 109/L
  • ANC ≥1.5 x 109/L
  • CD4 ≥ 200 total cells/mm3
  • Hemoglobin ≥ 80g/L
  • Platelet count ≥ 100 x 109/L
  • Acceptable coagulation status: INR ≤ 1.4
  • Creatinine ≤ 2 x ULN
  • Serum Sodium, Potassium and Calcium levels ≤ Grade 1
  • If patients are diabetic or have a screening random glucose > 8.9mmol/L, a fasting glucose must be done and results must be WNL or Grade 1 in order to be eligible for the study.
  • For patients who are sexually active: patient must be able and willing to abstain from sex during JX-594 treatment period (to prevent pregnancy) and willing to use barrier method for at least 6 weeks after the last JX-594 treatment (to protect partner against infection).
  • Able and willing to sign an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)/Research Ethics Board (REB)-approved written consent form Able and willing to comply with study procedures and follow-up examinations, including compliance with the "Infection Control Guidelines for Patients" contained within the written consent form.

Exclusion Criteria:

  • Prior local-regional treatment (including hepatic arterial infusion, hepatic embolization, radiofrequency ablation) for tumor downstaging. Prior adjuvant chemotherapy will be accepted as long as the duration between chemotherapy and the development of metastases has been >8 weeks.
  • Pregnant or nursing an infant
  • Known myeloproliferative disorders requiring systemic therapy
  • Significant immunodeficiency due to underlying illness (e.g. HIV/AIDS) and/or medication (e.g. high dose systemic corticosteroids taken for more than 4 weeks within the preceding 3 months)
  • History of severe exfoliative skin condition (e.g. eczema or atopic dermatitis requiring systemic therapy for more than 4 weeks)
  • Tumor(s) invading a major vascular structure (e.g. carotid artery)
  • Clinically significant and/or rapidly accumulating ascites, pericardial and/or pleural effusions
  • Clinically significant active infection, requiring systemic antibiotic therapy, or uncontrolled medical condition which would, in the opinion of the principle investigator, impair the ability of the subject to receive protocol therapy
  • Severe or unstable cardiac disease, including significant coronary artery disease requiring angioplasty or stenting within the preceding 12 months, unless well-controlled and on stable medical therapy for at least 3 months
  • Known viable CNS malignancy (history of completely resected or irradiated brain metastases allowed)
  • Chronic use of anti-platelet or anti-coagulation medication that cannot be temporarily discontinued for at least seven days prior to treatment with JX-594. (Note: the following are allowed: low dose aspirin ≤ 100 mg, low dose coumadin as long as INR ≤ 1.4 and low-dose heparin to maintain port access)
  • Use of the following anti-viral agents: ribavirin, adefovir, cidofovir (at least 7 days prior to the first treatment), and PEG-IFN (at least 14 days prior to the first treatment).
  • Absolute contraindication to undergoing MRI scanning (e.g. pacemaker, paramagnetic intracranial aneurysm clip, inner ear implants, fragments of metal within the body, etc.).
  • Pulse oximetry O2 saturation < 90% at rest
  • Experienced a severe systemic reaction or side-effect as a result of a previous smallpox vaccination
  • Inability or unwillingness to give informed consent or comply with the procedures required in this protocol.
  • Patients with household contacts who meet any of these criteria will be excluded unless alternate living arrangements can be made during the patient's dosing period and for at least 7 days following the last dose of study medication
  • Pregnant or nursing an infant
  • Children < 1 year old
  • People with skin disease (eczema, atopic dermatitis and related diseases
  • Immunocompromised hosts (severe deficiencies in cell-mediated immunity, including AIDS, organ transplant recipients, hematologist malignancies)

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: JX-594 Intravenous infusion

At Day 1 patients will receive either an intratumoral injection or intravenous infusion. The treatment given is determined by the patient's tumor characteristics.

Patients with ≥ 2 qualifying intrahepatic CRC metastases, where at least one (1) tumor measures ≥ 1.5 cm LD and is injectable under radiographic guidance (e.g. ultrasound or CT guidance), will receive an intratumoral injection. Patients with only one (1) qualifying intrahepatic CRC metastasis, or with tumors < 1.5cm and/or no injectable tumors, will receive an intravenous infusion.

intratumoral or intravenous dosage: 10e9 pfu Intravenous: administered over 60 minutes Intratumoral: direct injection into a single liver lesion

Altri nomi:
  • JX-594
Sperimentale: JX-594 Intratumoral Injection

At Day 1 patients will receive either an intratumoral injection or intravenous infusion. The treatment given is determined by the patient's tumor characteristics.

Patients with ≥ 2 qualifying intrahepatic CRC metastases, where at least one (1) tumor measures ≥ 1.5 cm LD and is injectable under radiographic guidance (e.g. ultrasound or CT guidance), will receive an intratumoral injection. Patients with only one (1) qualifying intrahepatic CRC metastasis, or with tumors < 1.5cm and/or no injectable tumors, will receive an intravenous infusion.

intratumoral or intravenous dosage: 10e9 pfu Intravenous: administered over 60 minutes Intratumoral: direct injection into a single liver lesion

Altri nomi:
  • JX-594

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Delivery to and Replication Within Tumors
Lasso di tempo: Day 1, 3, 5, 8, 11, and 15

IT injection: replication and dissemination of JX-594 following injection of a single colorectal metastasis within the liver. A positive replication response is defined as a > 2-fold increase in viral genome concentration in the blood(as measured in the first 12 hours following injection) within the first 14 days following treatment.

Note: Viral genomes will be measured in the blood by Q-PCR at baseline, on Day 1 (15 minutes, 3 hours & 8 hours) post-treatment and on Days 3, 5, 8, 11 and 15.

IV infusion: assessment of viral gene & protein expression in histologic samples of tumor tissue

Day 1, 3, 5, 8, 11, and 15

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
JX-594 Spread to, and Replication Within, Non-injected Tumors After IT JX-594 Injection
Lasso di tempo: Day 1

JX-594 spread to, and replication within, non-injected tumors after IT JX-594 injection as measured by the presence of viral protein expression and/or LacZ expression in non-injected tumor sections from at least 1) two different non-consecutive cuts, both of which contain viable tumor tissue in at least 10 high power fields; and 2) at least 5 cells in one high power field show positive staining for viral protein and/ or LacZ expression

Day 1
Modified Choi Response Assessment
Lasso di tempo: Day 8-14

Modified Choi response assessment based on DCE-MRI at baseline and between Days 8 14 (within 7 days prior to surgical resection)

Day 8-14
Toxicity: Grade I-IV Adverse Events (According to CTCAE)
Lasso di tempo: Day 1- Day 43

Toxicity: Grade I-IV Adverse Events (according to CTCAE); including surgical complications such as delay of surgery, prolonged hospitalization, bleeding (monitor transfusion requirements), postoperative infections, bile leak, hepatic failure sepsis and death

Day 1- Day 43

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Rebecca C Auer, MD, OHRI

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio

1 ottobre 2011

Completamento primario (Effettivo)

1 gennaio 2012

Completamento dello studio (Effettivo)

1 marzo 2013

Date di iscrizione allo studio

Primo inviato

4 aprile 2011

Primo inviato che soddisfa i criteri di controllo qualità

5 aprile 2011

Primo Inserito (Stimato)

6 aprile 2011

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

2 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

9 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi